Trilavir E is a fixed-dose antiretroviral combination used for the treatment of HIV-1 infection. It contains Tenofovir Disoproxil Fumarate, Lamivudine, and Efavirenz, three potent antiviral agents that work together to control HIV replication. This combination helps reduce the viral load, improve immune function, and delay the progression of HIV to AIDS. It is generally taken as a once-daily tablet for convenient long-term therapy.

Mechanism of Action

1. Tenofovir Disoproxil Fumarate (TDF): A nucleotide reverse transcriptase inhibitor (NtRTI) that blocks the reverse transcriptase enzyme, preventing HIV from converting its RNA into DNA.

2. Lamivudine (3TC): A nucleoside reverse transcriptase inhibitor (NRTI) that incorporates into viral DNA, causing premature chain termination.

3. Efavirenz (EFV): A non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, disabling its function and further preventing viral replication.

   Uses

   • Treatment of HIV-1 infection in adults and adolescents.

   • Helps reduce viral load and increase CD4 cell count.

   • Part of combination antiretroviral therapy (ART) for effective long-term control of HIV infection.

   • Reduces the risk of HIV-related complications and transmission.

     Adverse Effects

     • Dizziness, headache, tiredness

     • Nausea, vomiting, diarrhea

     • Insomnia or abnormal dreams (Efavirenz-related)

     • Mild skin rash